CCI
JAZZ icon

Columbus Circle Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Columbus Circle Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,700
Closed -$2M – 221
2017
Q3 		$2M Buy
+13,700
New +$2.07M 0.03% 224

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Columbus Circle Investors's JAZZ Position: Q4 2017 in Review

Columbus Circle Investors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2017, closing a stake of 58,512 shares — an estimated $8.56M sold.

Columbus Circle Investors first reported a position in JAZZ in Q2 2013 and held it in 18 quarters. The position peaked at $50.7M in Q1 2014. 323 funds tracked by Wall St. Rank hold JAZZ as of Q4 2017.

  • Columbus Circle Investors reported no remaining Jazz Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 58,512 Jazz Pharmaceuticals shares in Q4 2017, an estimated $8.56M.
  • Columbus Circle Investors first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Columbus Circle Investors's Jazz Pharmaceuticals position peaked at $50.7M in Q1 2014.
  • 323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.